The British venture capital fund plans to start a process to divest the generics subsidiary of its investee Neuraxpharm.
The British venture capital fund Permira has contracted the services of Jefferies to launch the sale process of Inke, a Spanish pharmaceutical company that is part of Neuraxpharm and whose valuation could be between 150 and 200 million euros
